According to the Zhitong Finance App, Goli Pharmaceutical-B (01672.HK) announced that it has selected ASC48, a GIPR agonist that is expected to be the first of its kind (first-in-class) oral small molecule, and a fixed-dose compound formulation of the oral GLP-1R agonist ASC30 for clinical development. The ASC30 and ASC48 fixed-dose combination formulation (ASC30_48 FDC) targets GLP-1R and GIPR at the same time, and is expected to be the first “one-pill, once-daily)” oral obesity treatment of its kind.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.